Clinical Trial Detail

NCT ID NCT03425006
Title Pembrolizumab and Itacitinib (INCB039110) for NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Pennsylvania
Indications

lung non-small cell carcinoma

Therapies

Itacitinib + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST